Knowledge of tumor markers and the psychological consequences of tumor marker sampling in patients with gynecologic cancers

Anticancer Research

Volumn 20, Issue 2 B, 2000, Pages 1281-1284

  Mayerhofer, Klaus ^a   Bodner, Klaus ^a   Aktas, Caglayan ^a   Schindl, Monika ^a   Kaider, Alexandra ^b   Leodolter, Sepp ^a   Joura, Elmar A ^a   Kainz, Christian ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b NONE

Author keywords

Gynecologic cancer; Psychological burden; Tumor marker

Indexed keywords

TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BREAST CANCER; ENDOMETRIUM CANCER; FEAR; FEMALE; GYNECOLOGIC CANCER; HUMAN; MAJOR CLINICAL STUDY; NURSE; OVARY CANCER; PATIENT INFORMATION; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; SELF REPORT; UTERINE CERVIX CANCER; VAGINA CANCER; VULVA CANCER;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GENITAL NEOPLASMS, FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS; VAGINAL NEOPLASMS; VULVAR NEOPLASMS;

EID: 0034011856     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Altaras MM, Goldberg GL, Levin W, Bloch B, Darge L and Smith JA: The role of antigen 125 (CA 125) in the management of ovarian epithelial carcinomas. Gynecol Oncol 30: 26-34, 1988.
2. Avall-Lundqvist EH, Sjovall K, Nilsson BR and Eneroth PH: Prognostic sign[t]cance of pretreatment serum levels of sqamous cell carcinoma antigen and CA 125 in cervical carcinoma. Eur J Cancer 28A: 1695-1702, 1992.
3. Bast RC Jr, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, Zurawski VR and Knapp RC: A radioimmunoassay using a monoclonal antibody to monitor the course of epithelian ovarian cancer. N Engl J Med 309: 883-887, 1983
4. Bast RC Jr, Knauf S, Epenetos A, Dhokia B, Daly L, Tanner M, Soper J, Creasman W, Gall S and Knapp RC: Coordinative elevation of serum markers in ovarian cancer hut not in benign disease. Cancer 68: 1758-1763, 1991.
5. Vergote IB, Bormer OP and Abeler VM: Evaluation of serum CA 125 levels in the monitoring of ovarian cancer. Am J Obstet Gynecol 157: 88-92, 1987.
6. Kallioniemi OP, Oksa H, Aaran RK, Hietanen T, Lehtinen M and Koivula T: Serum CA 15-3 assay in the diagnosis and follow-up of breast cancer. Br J Cancer 58: 213-215, 1988.
7. hunter VJ, Daly L, Helms M, Soper JT, Berchuck A, Clarke-Pearson DL and Bast -RC: The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction. Am J Obstet Gynecol 163: 1164-1167, 1990.
8. Ngan HY, Chan SY, Wong LC, Choy DT and Ma HK: Serum sqamous cell carcinoma antigen in the monitoring of radiotherapy treatment response in carcinoma of the cervix. Gynecol Oncol 37: 260-263, 1990.
9. Rose PG, Baker S, Foumier L, Nelson BE and Hunter RE: Serum sqamous cell carcinoma antigen levels in invasive cervical cancer: prediction of response and recurrence. Am J Obstet Gynecol 168: 942-946, 1993.
10. Rose PG, Nelson BE, Fournier L and Hunter RE: Serum sqamous cell carcinoma, antigen levels in invasive vulvar cancer. J Surg Oncol 50: 183-186, 1992.
11. Rose PG, Sommers RM, Reale FR, Hunter RE, Fournier L and Nelson BE: Serial serum CA 125 measurements for evaluation of recurrence in patients with endometrial carcinoma. Obstet Gynecol 84: 12-16, 1994.
12. Sutherland H, Llewellyn-Thomas H, Lockwood G, Tritchler D and Till J: Cancer patients: their desire for information and participation in treatment decision. J Roy Soc Med 82: 260-263, 1989.
13. Lanzetta JT and Driscoll JM: Preference for information about an uncertain but unavoidable outcome. J Person Social Psychol 3: 96-102, 1996.
14. Cope H, David A and Mann A: "Maybe it's a virus?" Beliefs about viruses, symptom attributional style and psychological health. J Psychosomatic Res 38: 89-98, 1994.
15. Cassileth B, Zupkis C, Sutton-Smith K and March V: Information and participation preferences among cancer patients. Ann Int Med 92: 832-836, 1980.
16. Followfield L, Baum M and McGuire P: Addressing the needs of the conservatively treated cancer patient. J Roy Soc Med 80: 696-700, 1987.
17. Rodin J: Ageing and health: Effects of the sense of control. Science 233: 1271-1276, 1986.
18. Fioretti P, Gadducci A, Ferdeghini M, Bartolini T, Bianchi R and Facchini V: Correlation of CA 125 and CA 19-9 serum levels with clinical course and second-look findings in patients with ovarian carcinoma. Gynecol Oncol 28: 278-283, 1987.
19. Rustin GC, Gennings JN, Nelstrop AE, Covarrubias H, Lambert HE and Bagshawe KD: Use of CA-125 to predict survival of patients with ovarian carcinoma. North Thames Cooperative Group. J Clin Oncol 7: 1667-1671, 1989.
20. Bolli JA, Doering DL, Bosscher JR, Day TG, Rao CV, Owens K, Kelly B and Goldsmith J: Squamous cell carcinoma antigen: Clinical utility in squamous cell carcinoma of the uterine cervix. Gynecol Oncol 55: 169-173, 1994.
21. Holloway RW, To A, Moradi M, Boots L, Watson N and Shingleton HM: Monitoring the course of cervical carcinoma with the squamous cell carcinoma serum radioimmunoassay. Obstet Gynecol 74: 944-949, 1989.
22. Duk JM, Aalders JG, Fleuren GJ and de-Bruijn HW: CA-125: A useful marker in endometrial carcinoma. Am J Obstet Gynccol 155: 1097-1102, 1986.
23. Patsner B, Orr JW and Mann WJ: Use of serum CA-125 measurement in posttreatment surveillance of early-stage endometrial carcinoma. Am J Obstet Gynecol 162: 427-429, 1990.
24. Matorras R, Rodriguez-Escuderoi FJ, Diez J, Genolla J, Cruz-Fombellida J and Ruibal A: Monitoring endometrial adenocarcinoma with a four tumor marker combination. CA-125, squamous cell carcinoma antigen, CA-19-9, and CA-15-3. Acta Obstet Gynecol Scand 71: 458-464, 1992.
25. Evans AC and Berchuck A: Tumormarkers.In: Principles and practice of gynecologic oncology, second edition (Hoskins WJ, Perez CA and Young RC, eds). Philadelphia, Lippincott-Raven Publishers, 1997, pp 177-195.
26. Neunteufel W, Tatra G and Bieglmayer C: Serum squamous carcinoma antigen levels in women with neoplasms of the lower genital tract and in healthy controls. Arch Gynecol Obstet 246: 243-250, 1989.